Document Type : Original Article
Authors
- Enayat Anvari 1
- Atefe Ghamar Talepoor 2
- Mahsa Eshkevar Vakili 2
- Narges Karimi 2
- MohammadReza Ataollahi 3
- Gelareh Najafi 1
- Dieter Kabelitz 4
- Iraj Ahmadi 1
- Kurosh Kalantar 2, 5
1 Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
2 Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Immunology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
4 Institute of Immunology, University of Kiel, Kiel, Germany
5 Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2).
Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2.
Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique.
Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, p < 0.0001) and the second dose (10. 36 μg/ml vs. 4.88 μg/ml, p < 0.0001).
Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.
Keywords
)